ClinicalTrials.gg

Program

Naltrexone

Also written as “naltrexone implant”, “Naltrexone and Acetaminophen” and “Naltrexone and Acetaminophen-High Dose”.

Its studies are mostly in Obesity · Opioid-Related Disorders · Migraine Disorders · Alcoholism · Depression, led by 14 companies.

Furthest: phase 4, since Dec 18, 201537 company-led studies, 5 open or runningNext primary completion: Apr 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Orexigen Therapeutics110 open or runningphase 4since Dec 18, 2015Aug 14, 2006none ahead
Allodynic Therapeutics60 open or runningphase 3since Jun 8, 2017Feb 17, 2017none ahead
Shenzhen Sciencare Medical Industries42 open or runningphase 3since Feb 8, 2026Jun 16, 2023Apr 1, 2027phase 3 · NCT07433413
AgelessRx31 open or runningphase 3since Dec 18, 2024Oct 26, 2020none ahead
Go Medical Industries Pty31 open or runningphase 2since May 16, 2022Jan 17, 2019Jul 1, 2029phase 2 · NCT05382091
Pfizer20 open or runningphase 3since Sep 2, 2011Sep 2, 2011none ahead
Alkermes10 open or runningphase 3since Feb 26, 2016Feb 26, 2016none ahead
Annette C. Toledano MD10 open or runningphase 2since Aug 11, 2011Aug 11, 2011none ahead
Delpor10 open or runningphase 1since Mar 7, 2022Mar 7, 2022none ahead
elite-laboratories-inc10 open or runningphase 3since Feb 17, 2015Feb 17, 2015none ahead
pain-therapeutics10 open or runningphase 2since Aug 12, 2008Aug 12, 2008none ahead
Takeda10 open or runningphase 4since Nov 24, 2015Nov 24, 2015none ahead
the-taub-group10 open or runningphase 4since Dec 21, 2017Dec 21, 2017none ahead
Truway Health11 open or runningphase 2since Oct 23, 2025Oct 23, 2025Oct 23, 2034phase 2 · NCT07221565

Also a collaborator on its studies: the-emmes-company-llc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 22 studies since Aug 14, 2006.

  1. Dec 21, 2017the-taub-group's first study: phase 4 study in DepressionNew to the-taub-groupthe-taub-group · NCT03386448 · 14 enrolled · United States
  2. Jan 17, 2019Go Medical Industries Pty's first study: phase 1 study in Opioid-Related DisordersNew to Go Medical Industries PtyGo Medical Industries Pty · NCT03810495 · 20 enrolled · United States
  3. Oct 26, 2020AgelessRx's first studies: 2 phase 2 studies in COVID-19New to AgelessRxAgelessRx · NCT04604704, NCT04604678
  4. Jan 17, 2021Phase 1 study in Opioid-Related DisordersGo Medical Industries Pty · NCT04716881 · 9 enrolled · United States
  5. Mar 7, 2022Delpor's first study: phase 1 study in Behavior, AddictiveNew to DelporDelpor · NCT05304364 · 10 enrolled · Australia
  6. May 16, 2022Phase 2 study in Opioid-Related DisordersGo Medical Industries Pty · NCT05382091 · 250 planned
  7. Dec 27, 2022Phase 2 study in Migraine DisordersAllodynic Therapeutics · NCT05685225 · United States
  8. Jun 16, 2023Shenzhen Sciencare Medical Industries's first study: phase 1 study in AUDNew to Shenzhen Sciencare Medical IndustriesShenzhen Sciencare Medical Industries · NCT05919017 · 60 planned · China
  9. Jan 30, 2024Phase 2 study in Migraine DisordersAllodynic Therapeutics · NCT06245902 · 92 enrolled · United States
  10. Dec 18, 2024Phase 3 study in LongevityAgelessRx · NCT07092618 · 150 planned · United States
  11. Jun 3, 2025Phase 2 study in Opioid-Related DisordersShenzhen Sciencare Medical Industries · NCT07014644 · 31 enrolled · China
  12. Oct 23, 2025Truway Health's first study: phase 2 study in Lupus Erythematosus, SystemicNew to Truway HealthTruway Health · NCT07221565 · 120 planned · United States
  13. Dec 30, 2025Phase 2 study in AUDShenzhen Sciencare Medical Industries · NCT07333638 · 210 enrolled · China
  14. Feb 8, 2026Phase 3 study in AlcoholismPhase 3 reachedShenzhen Sciencare Medical Industries · NCT07433413 · 240 planned

Ahead

  1. Apr 1, 2027Primary completion: phase 3 study in AlcoholismShenzhen Sciencare Medical Industries · NCT07433413
  2. Jul 1, 2029Primary completion: phase 2 study in Opioid-Related DisordersGo Medical Industries Pty · NCT05382091
  3. Oct 23, 2034Primary completion: phase 2 study in Lupus Erythematosus, SystemicTruway Health · NCT07221565

TargetBeta

“Opioid receptors; mu/kappa/delta antagonist; Opioid receptors; mu/kappa/delta antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
nalmefeneruleH. Lundbeckphase 420
NalbuphineruleTrevi Therapeuticsphase 420
cebranopadolruleTris Pharmaphase 318

Studies

All 37 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07433413Alcoholism3Not yet recruitingShenzhen Sciencare Medical IndustriesApr 1, 2027240
NCT07333638AUD · China2CompletedShenzhen Sciencare Medical IndustriesSep 27, 2024210
NCT07221565Lupus Erythematosus, Systemic · United States2By invitationTruway HealthOct 23, 2034120
NCT07014644Opioid-Related Disorders · China2CompletedShenzhen Sciencare Medical IndustriesMay 13, 202031
NCT07092618Longevity · United States3RecruitingAgelessRxAug 2025150
NCT06245902Migraine Disorders · United States2CompletedAllodynic TherapeuticsFeb 8, 201892
NCT05919017AUD · China1RecruitingShenzhen Sciencare Medical IndustriesDec 31, 202360
NCT05685225Migraine Disorders · United States2WithdrawnAllodynic TherapeuticsDec 2, 20250
NCT05382091Opioid-Related Disorders2Not yet recruitingGo Medical Industries PtyJul 1, 2029250
NCT05304364Behavior, Addictive · Australia1CompletedDelporOct 21, 202210
NCT04716881Opioid-Related Disorders · United States1CompletedGo Medical Industries PtyApr 4, 20229
NCT04604704COVID-19 · United States2CompletedAgelessRxJan 23, 202336
NCT04604678COVID-19 · United States2WithdrawnAgelessRxAug 20210
NCT03810495Opioid-Related Disorders · United States1CompletedGo Medical Industries PtyMar 18, 202120
NCT03386448Depression · United States4Completedthe-taub-groupNov 20, 201814
NCT03201393Radiculopathy · United States2CompletedAllodynic TherapeuticsJul 26, 201812
NCT03194555Headache · United States2CompletedAllodynic TherapeuticsJul 26, 201812
NCT03185143Migraine With and Without Aura · United States3CompletedAllodynic TherapeuticsMay 7, 201836
NCT03061734Migraine Disorders · United States2CompletedAllodynic TherapeuticsFeb 8, 201892
NCT02745912Healthy Subjects1CompletedOrexigen TherapeuticsJun 201630
NCT02735603Heart Repolarization · United States1CompletedOrexigen TherapeuticsJul 201684
NCT02696434Opioid-Related Disorders · United States3CompletedAlkermesNov 2017101
NCT02638129Obesity · United States4TerminatedOrexigen TherapeuticsJun 201667
NCT02616315Weight Regain Post Bariatric Surgery · United States4WithdrawnTakedaOct 20170
NCT02391571Substance Withdrawal Syndrome · United States3Completedelite-laboratories-incMar 201526
NCT01825447Healthy · United States1CompletedPfizerSep 201389
NCT01428583Chronic Noncancer Pain · United States3CompletedPfizerMay 2012395
NCT01415895Back Pain · United States2CompletedAnnette C. Toledano MDFeb 201378
NCT00758966Obsessive-Compulsive Disorder · United States2TerminatedOrexigen TherapeuticsDec 20088
NCT00734461Opioid-Related Disorders · United States2Completedpain-therapeuticsMar 200914
NCT00711477Obesity · United States2CompletedOrexigen TherapeuticsJun 201046
NCT00624858Depression · United States2CompletedOrexigen TherapeuticsJul 200925
NCT00567255Obesity · United States3CompletedOrexigen TherapeuticsJun 20091,496
NCT00532779Obesity · United States3CompletedOrexigen TherapeuticsMay 20091,742
NCT00474630Obesity · United States3CompletedOrexigen TherapeuticsJun 2009505
NCT00456521Obesity · United States3CompletedOrexigen TherapeuticsDec 2008793
NCT00364871Obesity · United States2CompletedOrexigen TherapeuticsMar 2007410

How it is read

Names in the registry

  • “Naltrexone”, 5 entries
  • “naltrexone implant”, 2 entries
  • “Naltrexone and Acetaminophen”, 2 entries
  • “Naltrexone and Acetaminophen-High Dose”, 2 entries
  • “Naltrexone SR 32 mg/bupropion SR 360 mg/day”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Naltrexone (Orexigen Therapeutics): development program | ClinicalTrials.gg